Fig. 1. Patients with metastatic pancreatic cancer and FGFR2 fusions demonstrate response and clinical benefit when treated with FGFR kinase inhibitors.

A Overview of treatment time course in four patients with metastatic pancreatic cancer who received FGFR kinase inhibitors. Patient 1 had stable disease as best response, while patient 2-4 experienced partial responses. B Partial response to FGFR kinase inhibitor infigratinib after 10 months of treatment in patient 3 demonstrated by decreased size of lung metastases. Left is pretreatment CT scans and right is after 10 months on infigratinib. C Serial monitoring of CA19-9 and plasma cell free DNA for FGFR2 fusion during FGFR inhibitor targeted therapy. Patient 4 developed known FGFR2 resistance mutations alongside of his fusion VAF (%). Areas shaded in blue represent FGFR inhibitor treatment, areas shaded in gray represent chemotherapy treatment, and non-shaded areas represent no treatment. VAF, Variant Allele Frequency.